1 – 9 of 9
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
(
- Contribution to journal › Article
- 2014
-
Mark
GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma.
(
- Contribution to journal › Article
- 2013
-
Mark
Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the wnt/beta-catenin signaling pathway.
(
- Contribution to journal › Article
- 2012
-
Mark
Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches
(
- Contribution to journal › Article
-
Mark
Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data
(
- Contribution to journal › Article
- 2011
-
Mark
Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study
(
- Contribution to journal › Article
- 2010
-
Mark
Heterogeneous and Complex Rearrangements of Chromosome Arm 6q in Chondromyxoid Fibroma. Delineation of Breakpoints and Analysis of Candidate Target Genes.
(
- Contribution to journal › Article
- 2009
-
Mark
No Genomic Aberrations in Langerhans Cell Histiocytosis as Assessed by Diverse Molecular Technologies
(
- Contribution to journal › Article
-
Mark
Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors.
(
- Contribution to journal › Article